Uncontrolled Viral Replication as a Risk Factor for Non-AIDS Severe Clinical Events in HIV-Infected Patients on Long-Term Antiretroviral Therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study

被引:41
作者
Ferry, Tristan [2 ]
Raffi, Francois [3 ]
Collin-Filleul, Fideline [4 ]
Dupon, Michel [5 ]
Dellamonica, Pierre [6 ]
Waldner, Anne [7 ]
Strady, Christophe [8 ]
Chene, Genevieve [4 ]
Leport, Catherine [9 ]
Le Moing, Vincent [1 ]
机构
[1] Univ Montpellier 1, CHU Montpellier, Serv Malad Infect & Trop, Hop Gui Chauliac,UMR 145, F-34000 Montpellier, France
[2] Univ Lyon 1, Hop Croix Rousse, Hosp Civils Lyon, Serv Malad Infect & Trop, F-69365 Lyon, France
[3] CHU Nantes, Hop Hotel Dieu, Serv Malad Infect, F-44035 Nantes 01, France
[4] Univ Victor Segalen 2, INSERM, U897, Bordeaux, France
[5] CHU Bordeaux, Hop Pellegrin, Serv Malad Infect B, Bordeaux, France
[6] Univ Nice Sophia Antipolis, CHU Nice, Serv Malad Infect, Nice, France
[7] CHU Dijon, Serv Malad Infect, Dijon, France
[8] CHU Reims, Serv Malad Infect, Reims, France
[9] Univ Paris 07, Lab Rech Pathol Infect, Paris, France
关键词
cART; HIV; morbidity; non-AIDS events; viral load; GENERAL-POPULATION; MORTALITY-RATES; VIRUS; ADULTS; DEATH; DISEASE; CANCERS; ERA; INTERRUPTION; INITIATION;
D O I
10.1097/QAI.0b013e3181acb65f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term combination antiretroviral therapy (cART). Methods: A validation committee reviewed each severe clinical event that occurred in the APROCO/COPILOTE (ANRS CO8) cohort that enrolled 1281 patients in 1997-1999 at the initiation of cART containing protease inhibitor. Probability of the Occurrence of a first non-AIDS, cART-related, and AIDS-defining event was estimated, and potential determinants were Studied using Cox regression models. Results: During a median follow-up of 7.3 years, the incidence of non-AIDS events was higher than that of cART-rclated and AIDS-defining events (10.5, 3.6, and 2.6 per 100 patient-years, respectively). Bacterial (mainly airway) infections were the most frequent non-AIDS events (23.4%) followed by non-AIDS-defining malignancies and cardiovascular events (both 9.5%). Factors independently associated with the occurrence of a first non-AIDS event were age >60 years [hazard ratio (HR) 2.1; 95% confidence interval (CI): 1.3 to 3.2] and CD4 < 100 cells per milliliter (HR 2.5; 95% CI: 1.8 to 3.6) but also plasma HIV RNA > 4 log(10) copies per milliliter at the time of the event (HR 1.9; 95% CI: 1.5 to 2.5). Conclusion: Optimization and permanent continuation of long-term antiretroviral therapy in HIV-infected patients is the best strategy to prevent or reduce the occurrence of non-AIDS severe morbidity.
引用
收藏
页码:407 / 415
页数:9
相关论文
共 26 条
[1]   Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy [J].
Bonnet, F ;
Lewden, C ;
May, T ;
Heripret, L ;
Jougla, E ;
Bevilacqua, S ;
Costagliola, D ;
Salmon, D ;
Chêne, G ;
Morlat, P .
CANCER, 2004, 101 (02) :317-324
[2]   Trends and determinants of severe morbidity in HIV-infected patients:: The ANRS CO3 Aquitaine Cohort, 2000-2004 [J].
Bonnet, Fabrice ;
Chene, G. ;
Thiebaut, R. ;
Dupon, M. ;
Lawson-Ayayi, S. ;
Pellegrin, J. L. ;
Dabis, F. ;
Morlat, P. .
HIV MEDICINE, 2007, 8 (08) :547-554
[3]   HIV disease: fallout from a mucosal catastrophe? [J].
Brenchley, JM ;
Price, DA ;
Douek, DC .
NATURE IMMUNOLOGY, 2006, 7 (03) :235-239
[4]  
BRUYAND M, 2008, 15 C RETR OPP INF FE
[5]   Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia [J].
Burns-Naas, LA ;
Zorbas, M ;
Jessen, B ;
Evering, W ;
Stevens, G ;
Ivett, JL ;
Ryan, TE ;
Cook, JC ;
Capen, CC ;
Chen, M ;
Furman, G ;
Theiss, JC ;
Webber, S ;
Wu, E ;
Shetty, B ;
Gasser, R ;
McClain, RM .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2005, 24 (12) :643-654
[6]   Comparisons of causes of death and mortality rates among HIV-infected persons - Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras [J].
Crum, NF ;
Riffenburgh, RH ;
Wegner, S ;
Agan, BK ;
Tasker, SA ;
Spooner, KM ;
Armstrong, AW ;
Fraser, S ;
Wallace, MR .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (02) :194-200
[7]   CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial):: a randomised trial [J].
Danel, Christine ;
Moh, Raoul ;
Minga, Albert ;
Anzian, Amani ;
Ba-Gomis, Olivier ;
Kanga, Constance ;
Nzunetu, Gustave ;
Gabillard, Delphine ;
Rouet, Francois ;
Sorho, Souleymane ;
Chaix, Marie-Laure ;
Eholie, Serge ;
Menan, Herve ;
Sauvageot, Delphine ;
Bissagnene, Emmanuel ;
Salamon, Roger ;
Anglaret, Xavier .
LANCET, 2006, 367 (9527) :1981-1989
[8]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[9]   An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549. [J].
ElSolh, A ;
Kumar, NM ;
Nair, MPN ;
Schwartz, SA ;
LwebugaMukasa, JS .
IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (03) :351-370
[10]   THE PROGNOSTIC VALUE OF CELLULAR AND SEROLOGIC MARKERS IN INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].
FAHEY, JL ;
TAYLOR, JMG ;
DETELS, R ;
HOFMANN, B ;
MELMED, R ;
NISHANIAN, P ;
GIORGI, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (03) :166-172